The estimated Net Worth of Ivor Macleod is at least 602 千$ dollars as of 17 November 2021. Mr Macleod owns over 15,000 units of Athersys Inc stock worth over 14,922$ and over the last 5 years he sold ATHX stock worth over 0$. In addition, he makes 587,214$ as Chief Financial Officer & Principal Accounting Officer at Athersys Inc.
Mr has made over 1 trades of the Athersys Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 15,000 units of ATHX stock worth 17,700$ on 17 November 2021.
The largest trade he's ever made was buying 15,000 units of Athersys Inc stock on 17 November 2021 worth over 17,700$. On average, Mr trades about 1,500 units every 0 days since 2020. As of 17 November 2021 he still owns at least 146,583 units of Athersys Inc stock.
You can see the complete history of Mr Macleod stock trades at the bottom of the page.
Ivor Macleod CPA, M.B.A. is the Chief Financial Officer & Principal Accounting Officer at Athersys Inc.
As the Chief Financial Officer & Principal Accounting Officer of Athersys Inc, the total compensation of Mr A at Athersys Inc is 587,214$. There are 4 executives at Athersys Inc getting paid more, with Gil Van Bokkelen having the highest compensation of 1,596,650$.
Mr A is 59, he's been the Chief Financial Officer & Principal Accounting Officer of Athersys Inc since . There are 4 older and 9 younger executives at Athersys Inc. The oldest executive at Athersys Inc is Lorin Randall, 76, who is the Independent Director.
Over the last 17 years, insiders at Athersys Inc have traded over 3,715,462$ worth of Athersys Inc stock and bought 2,242,389 units worth 3,620,264$ . The most active insiders traders include Advisors Llc Orbi Med Capit...、Michael B Sheffery、Jordan Davis. On average, Athersys Inc executives and independent directors trade stock every 43 days with the average trade being worth of 3,231$. The most recent stock trade was executed by Daniel A. Camardo on 22 November 2022, trading 100,000 units of ATHX stock currently worth 55,000$.
athersys is a clinical stage biopharmaceutical company with a growing pipeline of highly differentiated, potential best in class therapeutics to treat significant and life-threatening diseases. we are engaged in the discovery and development of innovative new medicines designed to extend and enhance the quality of human life. through the application of our proprietary technologies, we have established a pipeline of therapeutic product development programs in multiple disease areas. this pipeline includes both stem cell therapy and pharmaceuticals.
Athersys Inc executives and other stock owners filed with the SEC include: